Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rank in Stocks #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Share Price
$0.00047446
Market Cap
$82.80
Change (1 day)
0.00%
Change (1 year)
-98.16%
Country
FR
Trade Neovacs S.A. (ALNEV)

Category

Stock price history for Neovacs S.A. (ALNEV)
Highest end of day price: $0.00 on 2026-04-01

Lowest end of day price: $55.15K on 2010-04-01
Stock price history of Neovacs S.A. from 2010 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 0.00%
2025 -99.78%
2024 592,903.23%
2023 -96.32%
2022 -99.92%
2021 -98.03%
2020 -37.62%
2019 -71.75%
2018 -62.61%
2017 -24.49%
2016 -11.42%
2015 -67.56%
2014 9.35%
2013 -13.08%
2012 -30.76%
2011 40.12%
2010 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$40.57 -35.48%
DK
$442.92 -8.84%
US
$754.58 37.38%
US
$309.11 96.60%
BE
$838.06 42.63%
NL